ABSTRACT
Resistance mutations to monoclonal antibody (mAb) therapy has been reported, but in the non-immunosuppressed population, it is unclear if in vivo emergence of SARS-CoV-2 resistance mutations alters either viral replication dynamics or therapeutic efficacy. In ACTIV-2/A5401, non-hospitalized participants with symptomatic SARS-CoV-2 infection were randomized to bamlanivimab (700mg or 7000mg) or placebo. Treatment-emergent resistance mutations were significantly more likely detected after bamlanivimab 700mg treatment than placebo (7% of 111 vs 0% of 112 participants, P=0.003). There were no treatment-emergent resistance mutations among the 48 participants who received bamlanivimab 7000mg. Participants with emerging mAb resistant virus had significantly higher pre-treatment nasopharyngeal and anterior nasal viral load. Intensive respiratory tract viral sampling revealed the dynamic nature of SARS-CoV-2 evolution, with evidence of rapid and sustained viral rebound after emergence of resistance mutations, and worsened symptom severity. Participants with emerging bamlanivimab resistance often accumulated additional polymorphisms found in current variants of concern/interest and associated with immune escape. These results highlight the potential for rapid emergence of resistance during mAb monotherapy treatment, resulting in prolonged high level respiratory tract viral loads and clinical worsening. Careful virologic assessment should be prioritized during the development and clinical implementation of antiviral treatments for COVID-19.
Competing Interest Statement
KWC has received research funding to the institution from Merck Sharpe & Dohme. PK and AN are employees and shareholders of Eli Lilly. ALG reports contract testing from Abbott and research support from Merck and Gilead. ESD has consulted for Gilead, Merck and ViiV and received research support from Gilead and ViiV. ASP has consulted for Amphylx Pharmaceticals. DMS has consulted for Bayer Pharmaceuticals, Linear Therapies, Matrix Biomed, FluxErgy and Brio Clinical. JZL has consulted for Abbvie.
Clinical Trial
NCT04518410
Funding Statement
This study was supported by the National Institute of Allergy and Infectious Diseases ACTIV-2/A5401 ClinicalTrials.gov number NCT04518410.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics oversight was performed by a central IRB (Advarra). Informed consent was obtained from all participants.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial support: This study was supported by the National Institute of Allergy and Infectious Diseases; ACTIV- 2/A5401 ClinicalTrials.gov number NCT04518410. Portions of this work were performed under the auspices of the U.S. Department of Energy through Los Alamos National Laboratory (LANL), which is operated by Triad National Security, LLC for the National Nuclear Security Administration of the U.S. Department of Energy (contract No. 89233218CNA000001). The work was also supported by LANL’s Laboratory Directed Research and Development program (projects No. 20200743ER, 20200695ER, and 20210730ER), by NIH grants R01-AI028433, R01-OD011095 (ASP), R01-AI15270301 (RK) and R01-AI116868 (RMR), by the Defense Advanced Research Projects Agency (contract No. HR0011938513) and by the DOE Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE National Laboratories focused on response to COVID-19, with funding provided by the Coronavirus CARES Act.
Disclosures: KWC has received research funding to the institution from Merck Sharpe & Dohme. PK and AN are employees and shareholders of Eli Lilly. ALG reports contract testing from Abbott and research support from Merck and Gilead. ESD has consulted for Gilead, Merck and ViiV and received research support from Gilead and ViiV. ASP has consulted for Amphylx Pharmaceticals. DMS has consulted for Bayer Pharmaceuticals, Linear Therapies, Matrix Biomed, FluxErgy and Brio Clinical. JZL has consulted for Abbvie.
Data Availability
Data available subjected to author's consent.
